Literature DB >> 9381793

A virus-neutralizing epitope on the glycoprotein of rabies virus that contains Trp251 is a linear epitope.

T R Luo1, N Minamoto, H Ito, H Goto, S Hiraga, N Ito, M Sugiyama, T Kinjo.   

Abstract

We have established a hybridoma producing monoclonal antibody (MAb) against a linear epitope of glycoprotein (G protein) of the RC-HL strain of rabies virus. This MAb15-13 showed almost the same neutralizing activity to all of five rabies fixed strains, including RC-HL, and reacted to the denatured G protein in western blot analysis. To characterize and map this linear epitope, an antigenic variant NR15-13 was selected from RC-HL strain in the presence of neutralizing MAb15-13. The variant reacted with MAb15-13 in an immunofluorescent antibody test but was not neutralized by the antibody and the antibody did not bind to the variant G protein in a Western blot analysis. The variant NR15-13 had an amino acid substitution at position 251 of the G protein, where tryptophan of the parental RC-HL strain was replaced by arginine. Site-directed mutagenesis analysis using the expression system in simian COS7 cells revealed that a single amino acid substitution at 251-tryptophan by arginine on the G protein of the parental RC-HL strain abolished the antigenicity of the epitope for MAb15-13 in western blot analysis, and the replacement of 251-arginine by tryptophan recovered the activity. These results strongly suggest that tryptophan at position 251 on the G protein is essential for construction of the linear epitope against MAb15-13.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9381793     DOI: 10.1016/s0168-1702(97)00080-4

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis.

Authors:  Wilfred E Marissen; R Arjen Kramer; Amy Rice; William C Weldon; Michael Niezgoda; Milosz Faber; Jerry W Slootstra; Rob H Meloen; Marieke Clijsters-van der Horst; Therese J Visser; Mandy Jongeneelen; Sandra Thijsse; Mark Throsby; John de Kruif; Charles E Rupprecht; Bernhard Dietzschold; Jaap Goudsmit; Alexander B H Bakker
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis.

Authors:  Christophe Préhaud; Stéphanie Lay; Bernhard Dietzschold; Monique Lafon
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein.

Authors:  Shukra M Aavula; Sridevi V Nimmagadda; Neelakantam Biradhar; Samuel Sula; Dev Chandran; Rajendra Lingala; Srinivasan Alwar Villuppanoor
Journal:  Biotechnol Res Int       Date:  2011-10-05

4.  Re-emergence of rabies in the Guangxi province of Southern China.

Authors:  Hai-Bo Tang; Yan Pan; Xian-Kai Wei; Zhuan-Ling Lu; Wu Lu; Jian Yang; Xiao-Xia He; Lin-Juan Xie; Lan Zeng; Lie-Feng Zheng; Yi Xiong; Nobuyuki Minamoto; Ting Rong Luo
Journal:  PLoS Negl Trop Dis       Date:  2014-10-02

5.  Replication-incompetent rabies virus vector harboring glycoprotein gene of lymphocytic choriomeningitis virus (LCMV) protects mice from LCMV challenge.

Authors:  Mutsuyo Takayama-Ito; Chang-Kweng Lim; Yukie Yamaguchi; Guillermo Posadas-Herrera; Hirofumi Kato; Itoe Iizuka; Md Taimur Islam; Kinjiro Morimoto; Masayuki Saijo
Journal:  PLoS Negl Trop Dis       Date:  2018-04-16

6.  Antigenic variations of recent street rabies virus.

Authors:  Wenbo Wang; Jian Ma; Jianhui Nie; Jia Li; Shouchun Cao; Lan Wang; Chuanfei Yu; Weijin Huang; Yuhua Li; Yongxin Yu; Mifang Liang; Brett Zirkle; Xiaojiang S Chen; Xuguang Li; Wei Kong; Youchun Wang
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

7.  Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans.

Authors:  Leonard Both; Craig van Dolleweerd; Edward Wright; Ashley C Banyard; Bianca Bulmer-Thomas; David Selden; Friedrich Altmann; Anthony R Fooks; Julian K-C Ma
Journal:  FASEB J       Date:  2013-01-31       Impact factor: 5.191

8.  Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.

Authors:  Hirofumi Kato; Mutsuyo Takayama-Ito; Itoe Iizuka-Shiota; Shuetsu Fukushi; Guillermo Posadas-Herrera; Madoka Horiya; Masaaki Satoh; Tomoki Yoshikawa; Souichi Yamada; Shizuko Harada; Hikaru Fujii; Miho Shibamura; Takuya Inagaki; Kinjiro Morimoto; Masayuki Saijo; Chang-Kweng Lim
Journal:  PLoS One       Date:  2019-10-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.